Normal Blood Sugar Is Not the Same as Diabetes Remission

Introduction

A person can have an HbA1c below the diabetes threshold and still have type 2 diabetes. If glucose is being held down by several medications, the treatment may be working extremely well—but that is glucose control, not medication-free remission.

A new multicenter phase III randomized trial makes this distinction unusually clear. Investigators studied 108 people relatively early after a type 2 diabetes diagnosis and compared an aggressive four-drug regimen with standard diabetes care. Treatment continued for 16 weeks, after which glucose-lowering medication was withdrawn from participants whose hyperglycemia had regressed.

The intensive regimen initially appeared more effective. Approximately 90% of participants receiving four medications achieved regression of hyperglycemia, compared with 77% receiving standard care. While treatment was active, aggressively targeting glucose produced the better laboratory result.

The more difficult test came after the medications were stopped. Remission required an HbA1c below 6.5% for at least 12 weeks without glucose-lowering medication, consistent with the international consensus definition of type 2 diabetes remission.

Medication-free remission occurred in 38.3% of the multidrug group and 43.8% of the standard-care group. The difference was not statistically significant. In other words, using four medications made glucose normalization more likely during treatment, but it did not make normal glucose more likely to persist after treatment was removed.

This does not mean the medications were ineffective or unnecessary. Lowering elevated glucose protects patients from the immediate and cumulative consequences of hyperglycemia. The trial instead reveals that controlling the marker and changing the underlying disease are different objectives.

Type 2 diabetes involves more than glucose. Hepatic and skeletal-muscle insulin resistance, excess liver and pancreatic fat, adipose-tissue dysfunction, hyperinsulinemia and declining beta-cell capacity may continue even when an HbA1c result looks normal. Some medications reduce glucose directly without fully eliminating the metabolic conditions that caused glucose to rise.

Remission asks whether the body can maintain glucose below the diabetes threshold after glucose-lowering therapy is withdrawn. Even then, remission is not the same as a permanent cure. Insulin resistance can return, beta-cell function can deteriorate and hyperglycemia may recur, which is why continued monitoring remains necessary.

In this article, we will examine what the trial tested, why aggressive glucose normalization did not produce more remission, how HbA1c can hide medication dependence and which markers—including fasting insulin, C-peptide, triglycerides and liver fat—can provide a more complete picture of metabolic recovery.

🎧 Listen to the Episode: The normal blood sugar trap

A normal HbA1c is worth celebrating—but it doesn't necessarily tell you how much insulin your body requires to maintain that glucose, what is happening inside your liver and pancreas, or whether the underlying metabolic pressure that contributed to type 2 diabetes has actually improved.

In this episode of The Health Pulse, we use a revealing clinical trial to explore the difference between pharmacologically controlling hyperglycemia and achieving sustained type 2 diabetes remission. We then go deeper into insulin resistance, ectopic fat, beta-cell function, the personal fat threshold, and the metabolic markers that can provide context beyond HbA1c alone.

▶️ Click play below to listen, or keep reading to discover why getting blood sugar back to “normal” may be an important milestone—but not the end of the metabolic story.

How the Trial Tested Remission

The study was designed around two separate outcomes that are often treated as though they mean the same thing: regression of hyperglycemia during treatment and remission after treatment withdrawal.

Investigators enrolled 108 adults relatively early in the course of type 2 diabetes across multiple clinical centers. Participants were randomly assigned either to an intensive four-drug regimen or to standard diabetes care. The purpose of the multidrug strategy was to normalize glucose rapidly by targeting several mechanisms simultaneously rather than gradually adding one medication at a time.

Treatment continued for 16 weeks. During this phase, researchers evaluated whether participants’ hyperglycemia had regressed sufficiently to permit withdrawal of glucose-lowering therapy. The intensive group reached that initial target more frequently: approximately 90% qualified to stop medication, compared with 77% in the standard-care group.

If the study had ended at that point, the multidrug regimen could have appeared clearly superior. More participants reached the desired glucose range while receiving treatment. However, the investigators continued monitoring after therapy was withdrawn.

To qualify as being in remission, participants had to maintain an HbA1c below 6.5% for at least 12 weeks without glucose-lowering medication. That medication-free period was essential. Without it, the researchers would have been measuring the effectiveness of treatment rather than the body’s ability to regulate glucose after treatment ended.

The final results changed the interpretation. Remission occurred in 38.3% of the intensive-treatment group and 43.8% of the standard-care group. The difference was not statistically significant, and the numerically higher percentage in the standard-care group should not be interpreted as proof that standard treatment produces more remission. The study instead found no evidence that the aggressive four-drug strategy improved the probability of remission.

This design exposes a common problem in diabetes research and routine care. An HbA1c result obtained while someone is taking medication answers the question, “Is the current treatment controlling glucose?” It does not answer, “Can this person maintain the same glucose level without treatment?”

The distinction does not diminish the importance of glucose control. Sustained hyperglycemia damages blood vessels, nerves, kidneys and other tissues, and medications can substantially reduce that exposure. But a therapy can protect a patient from hyperglycemia without producing a medication-independent change in the disease state.

The trial’s relatively short treatment period is also important. Sixteen weeks may be sufficient to normalize glucose, but it may not allow enough time for substantial reductions in visceral, hepatic or pancreatic fat, sustained improvement in insulin sensitivity or recovery of beta-cell function. The results apply to this specific treatment strategy and duration rather than proving that medication can never contribute to remission.

Key takeaway: The aggressive regimen was more effective at normalizing glucose while treatment was active, but it did not increase the likelihood that normal glucose would persist after the medications were withdrawn.

Why a Normal A1c Can Mislead

HbA1c is one of the most useful tests in diabetes care because it estimates average glucose exposure over approximately two to three months. When treatment lowers A1c, that improvement is real and clinically important. The confusion begins when a normal or near-normal result is interpreted as proof that type 2 diabetes has disappeared.

A person taking several glucose-lowering medications may have an HbA1c of 6.2%, while another person maintains the same result without medication. Their laboratory values are identical, but their metabolic states are not necessarily the same.

The first person’s glucose may be controlled because medication is suppressing liver glucose production, increasing urinary glucose loss, stimulating insulin secretion, slowing digestion or providing insulin directly. If the treatment is removed, glucose may rise again because the underlying insulin resistance and beta-cell limitations remain.

The second person may have improved insulin sensitivity enough to regulate glucose without pharmacological support. This could follow substantial weight loss, reduced liver and pancreatic fat, carbohydrate restriction, increased muscle activity, metabolic surgery or a combination of factors. That person may meet the definition of remission, although continued monitoring is still necessary.

A1c also does not show how much insulin is required to produce the result. Early in type 2 diabetes, the pancreas may secrete increasingly large amounts of insulin to maintain glucose near the normal range. This compensated hyperinsulinemia can persist for years before fasting glucose or A1c crosses the diabetes threshold.

Consequently, a normal A1c can coexist with significant insulin resistance. Glucose appears controlled because the pancreas is working harder, not because glucose regulation is metabolically effortless. Fasting insulin, C-peptide, triglycerides, waist circumference and liver fat can provide context that A1c alone cannot.

The reverse problem can also occur. A1c may remain mildly elevated even after insulin sensitivity has improved because it reflects several months of glucose exposure and changes gradually. Conditions affecting red blood cell production or survival—including anemia, recent blood loss, transfusion, kidney disease and some hemoglobin variants—can further distort the result.

Medication burden should not be treated as a moral failure, and medication-free status should not become the only definition of successful diabetes care. Some medications provide cardiovascular or kidney protection beyond their glucose-lowering effect and may remain appropriate even when glycemia improves. The treatment plan should reflect the patient’s complete risk profile.

The central point is narrower: A1c measures glycemic exposure. It does not independently measure insulin resistance, beta-cell health, medication dependence or the durability of glucose control.

Key takeaway: An HbA1c below 6.5% while taking glucose-lowering medication usually indicates well-controlled diabetes. Remission requires that the same result persist after medication has been withdrawn for at least three months.

Why More Medication Did Not Produce More Remission

The four-drug regimen was designed around a reasonable biological hypothesis. Rapidly lowering glucose soon after diagnosis may reduce glucotoxicity—the damaging effect that sustained hyperglycemia can have on pancreatic beta cells and insulin-sensitive tissues. Giving the pancreas a temporary period of reduced demand could theoretically allow beta-cell function to recover.

The trial confirms that aggressive treatment can normalize glucose quickly. What it did not demonstrate was that this temporary normalization created a more durable metabolic state after the medications were removed.

One explanation is that glucose-lowering drugs act downstream from several of the forces driving type 2 diabetes. They can reduce liver glucose production, stimulate insulin release, improve insulin sensitivity, delay glucose absorption or remove glucose through the urine. These effects lower the concentration of glucose in the bloodstream, but they do not necessarily eliminate the conditions that created the excess glucose.

Insulin resistance may remain present in the liver, skeletal muscle and adipose tissue. Excess liver and pancreatic fat may persist. The pancreas may still need to produce more insulin than normal, and its beta cells may retain only limited capacity to compensate once pharmacological support is withdrawn.

The 16-week treatment period may also have been too short to produce enough change in these underlying systems. Glucose can respond within days, while meaningful changes in body composition, ectopic fat and physical capacity may require months. The trial tested whether an intensive short medication course could induce remission; it did not test every possible combination of medication, nutrition, exercise and sustained weight reduction.

Weight loss appears to be one of the strongest predictors of remission because it can reduce the metabolic burden placed on both the liver and pancreas. In the DiRECT trial, 46% of participants receiving an intensive weight-management intervention achieved remission after one year. Remission was most common among those who lost the greatest amount of weight, although the ability to respond also depended on diabetes duration and remaining beta-cell function.

Carbohydrate restriction may approach the problem from another direction by reducing incoming glucose and the insulin required to manage it. Even before major weight loss occurs, a lower-carbohydrate diet can reduce post-meal glucose excursions and daily insulin demand. Whether that produces lasting remission depends on the person’s ability to maintain the metabolic improvement after medications are reduced.

Exercise contributes by increasing glucose disposal in skeletal muscle and helping preserve or build the body’s largest insulin-sensitive tissue. Sleep, stress hormones, alcohol exposure, medications that raise glucose and conditions such as fatty liver or sleep apnea may also affect whether normal glycemia persists.

Some diabetes medications can contribute to deeper disease modification. GLP-1–based therapies may produce substantial weight loss, while metformin, thiazolidinediones and other agents can influence insulin sensitivity or liver metabolism. The trial should therefore not be interpreted as evidence that medication only hides diabetes. It shows that a specific intensive regimen, used for 16 weeks, did not create more medication-free remission than standard care.

Key takeaway: Rapidly lowering glucose can relieve glucotoxicity, but durable remission usually requires sufficient improvement in insulin resistance, ectopic fat, beta-cell workload and the metabolic conditions that caused hyperglycemia.

What Actually Changes in Diabetes Remission?

Durable remission requires more than lowering the glucose circulating in the blood. The metabolic processes producing that glucose must also improve sufficiently for normal regulation to continue without glucose-lowering medication. Two of the most important changes involve the liver and the insulin-producing beta cells of the pancreas.

In type 2 diabetes, excess fat in the liver can interfere with insulin’s ability to suppress glucose production. The liver may continue releasing glucose into the bloodstream even when the body already has enough available. Reducing liver fat can restore some of this insulin sensitivity, decrease inappropriate hepatic glucose output and produce a rapid improvement in fasting glucose.

The mechanistic analysis from the Diabetes Remission Clinical Trial, or DiRECT, helps illustrate this process. Among participants receiving the weight-management intervention, average liver fat declined from approximately 16% to 3.1% after weight loss. Plasma triglycerides and pancreatic fat also decreased. However, losing ectopic fat did not guarantee remission for every participant.

The factor that most clearly distinguished responders was recovery of the pancreas’s first-phase insulin response. This is the rapid release of insulin that should occur immediately after glucose begins to rise. People who entered remission regained more of this early insulin response, allowing glucose to be controlled before it climbed excessively. Those who did not enter remission lost similar amounts of liver and pancreatic fat but did not demonstrate the same beta-cell recovery.

The DiRECT mechanistic study therefore suggests that reducing liver and pancreatic fat may create the conditions for remission, while the remaining capacity of the beta cells determines whether the pancreas can take advantage of those conditions. Participants who entered remission had lived with diabetes for a shorter average period than nonresponders, supporting the importance of intervening while beta-cell dysfunction may still be reversible.

This also explains why the same intervention can produce different results in different people. Individuals vary in how much ectopic fat they can tolerate before metabolic dysfunction develops—a concept sometimes described as the personal fat threshold. A person does not have to appear severely obese to accumulate metabolically harmful fat in the liver or pancreas, and two people who lose the same percentage of body weight may not experience identical beta-cell recovery.

Remission should not be confused with a permanent cure. Insulin resistance can return, liver fat can accumulate again and beta-cell function can deteriorate. Weight regain is one possible cause of relapse, but the underlying susceptibility to type 2 diabetes remains even when glucose stays below the diagnostic threshold. Continued monitoring is therefore necessary after remission has been achieved.

Key takeaway: Durable remission appears to require both relief of the metabolic pressure created by ectopic fat and enough remaining beta-cell capacity to restore appropriate insulin secretion. Lowering glucose alone does not establish that either change has occurred.

How Remission Should Be Measured

The formal definition of type 2 diabetes remission is intentionally simple. According to the international consensus report on diabetes remission, hemoglobin A1c must remain below 6.5% for at least three months after glucose-lowering medication has been discontinued. Medication withdrawal is essential because an acceptable A1c during treatment demonstrates effective control, not medication-independent remission.

HbA1c is useful because it reflects average glucose exposure over approximately three months. However, it does not reveal how much insulin the body required to maintain that glucose, whether the liver remains insulin resistant or how much functional capacity remains in the pancreatic beta cells. Two people with the same A1c can therefore have very different metabolic states.

Fasting glucose adds a more immediate view of hepatic glucose regulation. A consistently normal fasting value suggests that the liver is no longer releasing excessive glucose overnight, although it does not show how well the body handles a meal. When A1c is unreliable because of anemia, altered red blood cell survival, recent blood loss, transfusion or certain hemoglobin variants, fasting plasma glucose below 126 mg/dL may be used as an alternative remission criterion in appropriate clinical circumstances.

Fasting insulin can provide additional context about insulin demand. If glucose improves while fasting insulin remains markedly elevated, the pancreas may still be compensating for substantial insulin resistance. A decline in both glucose and insulin can suggest that the body requires less insulin to maintain glycemic control. HOMA-IR can combine fasting glucose and fasting insulin into an estimate of insulin resistance, but it is not part of the formal remission definition and does not have one universally accepted clinical cutoff.

C-peptide provides a different perspective. It is released alongside the body’s own insulin and can help estimate endogenous insulin production, particularly in someone who uses injected insulin. A very low C-peptide may indicate limited beta-cell reserve, while an elevated result may reflect compensatory insulin production caused by insulin resistance. Its interpretation depends on the glucose level at the time of testing, kidney function and whether the measurement was fasting or stimulated.

Liver fat, triglycerides, waist circumference and body-weight trends help evaluate the metabolic conditions underlying diabetes. Imaging can measure liver and pancreatic fat more directly, but it is not routinely required to certify remission. The DiRECT mechanistic findings show why these measurements remain valuable: reductions in ectopic fat can occur even when beta-cell function does not recover enough to produce remission.

Continuous glucose monitoring can reveal post-meal elevations and overnight patterns that A1c may conceal. A normal average glucose accompanied by repeated large excursions is not metabolically identical to a stable glucose profile. Nevertheless, CGM results currently supplement rather than replace the accepted laboratory definition.

Even after remission is documented, testing should continue at least annually. Glucose can rise again, and previous exposure to diabetes may leave a continuing risk of kidney, retinal, nerve and cardiovascular complications. Remission changes the current glycemic state; it does not erase the person’s metabolic history.

Key takeaway: HbA1c below 6.5% for at least three months without glucose-lowering medication establishes remission. Fasting glucose, fasting insulin, C-peptide, HOMA-IR, CGM patterns and liver-fat assessment can then show whether the underlying metabolic dysfunction has improved and how likely that remission may be to persist.

Can Medication Help Produce Remission?

The trial’s negative result does not mean diabetes medications are ineffective. The intensive four-drug regimen normalized glucose in 90% of participants during treatment. That is a meaningful therapeutic effect that can reduce symptoms, limit glucotoxicity and protect tissues from prolonged exposure to high glucose. What it did not accomplish was a higher rate of medication-free remission after treatment was removed.

Glucotoxicity occurs when persistently elevated glucose further impairs insulin sensitivity and beta-cell function. Lowering glucose early can interrupt this cycle and give beta cells a less stressful metabolic environment. In some people, this may create an opportunity for partial beta-cell recovery. However, removing glucotoxicity does not guarantee that the underlying insulin resistance, ectopic fat accumulation or beta-cell dysfunction has been reversed.

Different medications can produce the same glucose result through very different mechanisms. Some reduce the amount of glucose released by the liver. Others increase urinary glucose excretion, stimulate insulin secretion, slow digestion, suppress appetite or improve weight control. Injected insulin can normalize glucose by supplying more of the hormone needed to overcome insulin resistance. These treatments can be medically necessary and highly effective, but a normal glucose level does not reveal which mechanism produced it.

This is why medication dependence matters when discussing remission. If glucose remains normal only because treatment is actively suppressing it, the person has controlled diabetes. If glucose remains below the diagnostic threshold after medication has been withdrawn for at least three months, the person may meet the formal definition of remission.

Medication may still contribute indirectly to durable remission when it produces changes that persist beyond the treatment period. For example, a therapy that facilitates substantial loss of excess body fat may reduce liver fat, improve hepatic insulin sensitivity and lower the insulin demand placed on beta cells. In that situation, the lasting metabolic change—not simply the drug’s glucose-lowering action while it is present—may help support remission.

The distinction becomes complicated with medications prescribed for more than glucose. Some glucose-lowering drugs may be continued for weight management, cardiovascular protection or kidney protection even when A1c is below 6.5%. The international remission consensus acknowledges that when a glucose-lowering medication continues for another indication, medication-independent remission cannot be formally confirmed. That does not mean the person’s metabolic improvement is unimportant; it means the effect of the medication cannot be separated from the underlying condition.

The new multidrug trial also suggests that increasing the number or intensity of medications is not automatically equivalent to modifying more of the disease. The intensive group achieved better initial regression of hyperglycemia, yet the standard-care group had a numerically higher rate of medication-free remission. More aggressive biomarker suppression did not translate into greater durability after treatment stopped.

This result should not be interpreted as a reason to discontinue medication independently. Abrupt withdrawal can produce severe hyperglycemia, dehydration or other complications. Medication reduction should occur only when glucose patterns, A1c, symptoms and the broader clinical condition support it, with appropriate medical supervision.

Key takeaway: Medication can lower glucose, reduce glucotoxicity and sometimes help create the conditions for remission. However, its success during treatment does not prove that insulin resistance and beta-cell dysfunction have improved enough to maintain normal glucose after the medication is removed.

What Makes Remission More Likely?

The probability of remission is not determined by a single glucose value or treatment choice. It depends on whether the intervention can reduce the metabolic pressure driving diabetes and whether the pancreatic beta cells retain enough functional capacity to recover.

Time since diagnosis is one of the most important factors. In the DiRECT mechanistic study, participants who achieved remission had lived with diabetes for a shorter average period than those who did not. Earlier intervention may be more successful because some beta cells remain alive but functionally suppressed by excess glucose, fat exposure and continued demand for high insulin production.

As diabetes progresses, a greater proportion of beta-cell dysfunction may become difficult to reverse. This does not mean that people with long-standing diabetes cannot improve their glucose, insulin requirements or overall health. It means that complete medication-free remission becomes less predictable as the remaining capacity for normal insulin secretion declines.

Substantial and sustained weight loss is one of the strongest predictors of remission in people carrying excess body fat. A 2025 systematic review and meta-regression of randomized trials found a clear relationship between the amount of weight lost and the probability of remission. The biological benefit appears to come partly from reducing fat stored in metabolically sensitive locations such as the liver and pancreas, not simply from reaching a particular number on the scale.

The required weight loss differs among individuals. Some people can tolerate considerable subcutaneous fat before developing diabetes, while others accumulate harmful visceral and ectopic fat at a much lower body mass index. This personal fat threshold helps explain why type 2 diabetes can occur in people who do not appear obese and why remission should not be approached with one universal target weight.

Carbohydrate restriction may also improve the conditions associated with remission. Reducing dietary carbohydrate can lower post-meal glucose, decrease the amount of insulin required to process meals and reduce liver triglyceride production. Some people can reduce medication use substantially with a low-carbohydrate or ketogenic diet, although formal remission still requires an A1c below 6.5% after glucose-lowering medication has been stopped for the required period.

Physical activity contributes through another pathway. Skeletal muscle is a major destination for glucose after a meal. Resistance training can increase or preserve metabolically active muscle, while aerobic activity improves glucose disposal and mitochondrial function. Exercise alone may not produce the degree of weight or ectopic-fat reduction required for remission in every person, but it can improve insulin sensitivity and help prevent the loss of muscle during weight reduction.

Metabolic surgery produces some of the highest reported remission rates in eligible patients, particularly when performed earlier in the disease course. Its effects involve substantial weight loss, reduced liver fat and changes in appetite, bile-acid and gut-hormone signaling. Remission can still relapse after surgery, especially with weight regain or progressive loss of beta-cell function.

Lower baseline A1c, fewer required medications and the absence of injected insulin are often associated with a greater chance of remission, but these factors are not absolute rules. They frequently act as indirect indicators of shorter disease duration and greater remaining beta-cell reserve.

The most favorable situation is therefore not simply aggressive glucose treatment. It is early identification followed by an intervention that sustainably lowers insulin demand, reduces ectopic fat, improves insulin sensitivity and preserves beta-cell function.

Key takeaway: Remission is most likely when type 2 diabetes is addressed early, meaningful metabolic change is sustained and the pancreas retains enough beta-cell capacity to regulate glucose without medication. Weight loss is a powerful pathway, but liver fat, insulin demand, muscle health and individual fat tolerance also matter.

Why Remission Can Be Lost

Diabetes remission is a state that can persist for years, but it is not necessarily permanent. The biological susceptibility to insulin resistance and beta-cell dysfunction remains. If the metabolic pressure that originally produced diabetes returns, glucose can gradually rise again.

Weight regain is one of the clearest causes of relapse. When the body again exceeds its individual capacity to store fat safely beneath the skin, more fat may be delivered to the liver and pancreas. Liver insulin resistance can return, hepatic glucose production can increase and the pancreas may once again face a greater demand for insulin.

The two-year results from DiRECT demonstrated this relationship. Participants who maintained greater weight loss were considerably more likely to remain in remission. The longer-term follow-up also showed that remission became less common as some participants regained weight, emphasizing that maintaining the metabolic change is more difficult—and more important—than producing an initial decline in glucose.

Relapse can also occur without major weight gain. Aging, reduced physical activity, loss of skeletal muscle, poor sleep, chronic stress and certain medications can worsen insulin sensitivity. Corticosteroids are particularly capable of raising glucose, but antipsychotic medications, some immunosuppressants and other treatments may also contribute.

Illness, surgery and infection can temporarily increase glucose through cortisol, adrenaline and inflammatory signaling. A short period of elevated glucose does not necessarily mean remission has permanently ended. Persistent changes should be confirmed with laboratory testing and interpreted within the person’s clinical circumstances.

Beta-cell function may also continue to decline. Remission reduces the workload placed on the pancreas, but it does not guarantee that every beta cell has recovered or that progressive dysfunction has stopped. Someone with limited remaining beta-cell reserve may relapse even while maintaining many of the behaviors that originally produced remission.

This is why remission should be monitored rather than treated as a completed event. HbA1c should generally be reassessed at least annually and often more frequently during the first year, after medication changes or when weight and glucose patterns begin moving upward. Fasting glucose and continuous glucose monitoring may reveal deterioration before A1c crosses the diabetes threshold.

A rise in fasting insulin can be another early warning. The pancreas may initially compensate for renewed insulin resistance by producing more insulin, keeping glucose within the normal range. Waiting for glucose to become clearly diabetic again can miss this earlier hyperinsulinemic stage.

Previous diabetes complications also require continued surveillance. Kidney assessment, retinal examinations, blood-pressure management, foot care and cardiovascular-risk evaluation should continue as clinically appropriate. The international remission consensus cautions that prior hyperglycemia can continue to influence future complication risk even after remission occurs.

Relapse should not be viewed as personal failure. It indicates that the balance between insulin sensitivity, insulin demand and beta-cell capacity has shifted again. Recognizing the change early creates an opportunity to adjust nutrition, activity, weight management or medication before prolonged hyperglycemia returns.

Key takeaway: Remission can relapse when ectopic fat, insulin resistance or beta-cell stress returns. Sustaining remission requires ongoing metabolic management and laboratory monitoring—not simply one normal A1c after medication withdrawal.

How Lab Testing Helps

Diabetes remission cannot be evaluated from one glucose reading. A complete assessment should first determine whether formal remission has been achieved and then examine whether the metabolic abnormalities that produced diabetes are also improving.

Hemoglobin A1c remains the primary marker. It estimates average glucose exposure over the previous two to three months and provides the value used in the international remission definition. An A1c below 6.5% is encouraging, but the medication history must be reviewed before calling it remission. The same result while taking glucose-lowering medication represents controlled diabetes.

Fasting glucose helps assess how effectively insulin suppresses glucose production by the liver overnight. It may normalize relatively quickly when liver insulin sensitivity improves, sometimes before the full change becomes visible in A1c. Comparing fasting glucose with post-meal readings or continuous glucose monitoring can reveal whether glucose control remains stable throughout the day.

Fasting insulin adds information that A1c and glucose cannot provide alone. A person may maintain apparently normal glucose because the pancreas is producing an unusually large amount of insulin. If fasting insulin remains elevated, significant insulin resistance may still be present despite an acceptable glucose result. A decline in both fasting glucose and fasting insulin provides stronger evidence that insulin demand is falling.

HOMA-IR can be calculated from paired fasting glucose and fasting insulin measurements to estimate insulin resistance:

HOMA-IR is most useful for following trends under similar testing conditions. It is not part of the formal remission definition, and differences among insulin assays prevent one cutoff from applying reliably to every patient and laboratory.

C-peptide can help estimate how much insulin the pancreas is producing. A high C-peptide in the presence of normal or elevated glucose can support the presence of compensatory hyperinsulinemia. A low result may suggest limited beta-cell reserve, although it must be interpreted with the simultaneous glucose level, kidney function and medication history.

A comprehensive metabolic panel provides additional context through glucose, creatinine, estimated glomerular filtration rate and liver-related markers such as AST and ALT. These tests cannot measure liver fat directly, and normal liver enzymes do not exclude metabolic fatty liver disease. Imaging or elastography may be needed when liver fat or fibrosis risk requires more direct assessment.

A lipid panel can show whether triglycerides and HDL cholesterol are improving as insulin resistance decreases. ApoB can add a direct estimate of the number of atherogenic lipoprotein particles, which is important because normal glucose does not eliminate cardiovascular risk. Blood pressure, waist circumference and body composition complete the metabolic picture beyond laboratory results.

Kidney surveillance should continue even during remission. Serum creatinine and eGFR assess filtration, while a urine albumin-to-creatinine ratio can detect kidney injury that may not be visible in a routine blood panel. Previous exposure to diabetes can continue to affect vascular and kidney risk after glucose normalizes.

Quick Lab Mobile provides at-home blood collection in Miami for HbA1c, fasting glucose, fasting insulin, C-peptide, comprehensive metabolic panels, lipid testing, ApoB and other cardiometabolic markers requested by a healthcare professional. Testing these markers together can distinguish an improved A1c from a broader reduction in insulin resistance and metabolic risk.

Key takeaway: HbA1c determines whether glycemia meets the remission threshold, but fasting insulin, C-peptide, HOMA-IR, liver markers, kidney testing and cardiovascular biomarkers reveal what may be happening beneath the glucose result.

Conclusion

The new multidrug trial draws an important line between controlling type 2 diabetes and placing it into remission. During the 16-week treatment period, the aggressive four-drug strategy produced regression of hyperglycemia in 90% of participants, compared with 77% under standard care. Yet after treatment was withdrawn, medication-free remission occurred in 38.3% and 43.8%, respectively, with no significant advantage from the more intensive regimen.

The medications were effective at lowering glucose while they were being used. What they did not demonstrate was a superior ability to produce the lasting metabolic changes required for normal glucose regulation after treatment ended. Suppressing hyperglycemia and changing the underlying disease state are related objectives, but they are not interchangeable.

Durable remission appears to require a sufficient improvement in insulin sensitivity, reduced metabolic pressure from ectopic fat and enough remaining beta-cell capacity to regulate glucose without pharmacological support. This helps explain why early intervention, sustained weight reduction when appropriate, lower insulin demand, physical activity and preservation of skeletal muscle can matter beyond the A1c result itself.

Medication remains an important part of diabetes care. It can reduce glucotoxicity, prevent complications and sometimes help create the conditions for remission. The lesson from this trial is not that medication lacks value. It is that treatment success should not be defined exclusively by a glucose number obtained while therapy is still active.

A more complete assessment considers HbA1c, fasting glucose, fasting insulin, C-peptide, medication dependence, body composition, liver health and cardiovascular risk. These measurements help distinguish a controlled biomarker from a broader improvement in the metabolic processes responsible for type 2 diabetes.

Quick Lab Mobile offers convenient at-home blood collection in Miami for HbA1c, fasting glucose, fasting insulin, C-peptide, comprehensive metabolic panels, lipid testing, ApoB and other markers that can support diabetes and insulin-resistance assessment. Results should be interpreted with a qualified healthcare professional, and diabetes medication should never be reduced or discontinued without appropriate supervision.

👉 Need a specimen collection?. Book Now

Disclaimer:

The information provided in this blog, podcast, and associated content is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. The content shared is based on reputable sources, medical literature, and expert insights, but it should not be used as a replacement for direct consultation with a licensed healthcare provider.

No Doctor-Patient Relationship: Engaging with this content does not create a doctor-patient relationship between you and QuickLabMobile or any contributors. Always consult with a qualified physician, specialist, or healthcare professional before making any medical decisions, changing your treatment plan, or starting/stopping any medications.

Not a Substitute for Medical Advice: While we strive to provide accurate and up-to-date information, medicine is constantly evolving. New research, treatments, and medical recommendations may emerge, and individual health conditions can vary. Do not rely solely on this content for health decisions. If you are experiencing symptoms, have concerns about your health, or require medical assistance, seek immediate care from a licensed medical professional.

Emergency Situations: If you are experiencing a medical emergency, such as difficulty breathing, chest pain, signs of a stroke, or any other life-threatening condition, call 911 (or your local emergency services) immediately. Do not delay seeking emergency care based on information provided here.

Liability Disclaimer: QuickLabMobile, its contributors, and any associated entities do not assume liability for any damages, harm, or adverse outcomes resulting from the use, interpretation, or misuse of the information provided in this content. You are responsible for your own healthcare decisions and should always verify information with a trusted medical professional.

External Links & References: This content may include links to external sources, medical studies, or third-party websites for further reading. These links are provided for convenience and informational purposes only. QuickLabMobile does not endorse, control, or take responsibility for the accuracy of external content. Always verify information with authoritative sources such as the CDC, NIH, WHO.

Final Note: Your health is unique, and what works for one person may not be suitable for another. Stay informed, ask questions, and always prioritize professional medical guidance